Cumberland Pharmaceuticals vs Verrica Pharmaceuticals
CPIX and VRCA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CPIX and VRCA compare
Cumberland Pharmaceuticals is the larger company, worth 1.6 times as much as Verrica Pharmaceuticals ($99.3M against $63.9M).
Cumberland Pharmaceuticals grew revenue faster over the last twelve months (−1.1% versus −25.7% for Verrica Pharmaceuticals).
Cumberland Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −34.9% compared with −189% at Verrica Pharmaceuticals.
Cumberland Pharmaceuticals pays a dividend yielding 22.6%; Verrica Pharmaceuticals does not pay one.
Cumberland Pharmaceuticals scores higher on the StockData Score (5 against 4 for Verrica Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CPIX | VRCA |
|---|---|---|
| Size and price | ||
| Market cap | $99.3M | $63.9M |
| Share price | $6.63 | $3.72 |
| Change, 1 year | 232% | 1.6% |
| Change, 5 years | 166% | −96.7% |
| Beta (5Y) | 0.33 | 1.10 |
| Employees | 93 | 76 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 0 | 1 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/S | 3.2× | 2.8× (better) |
| P/B | 5.7× | – |
| P/FCF | 145× | – |
| FCF yield | 0.69% | – |
| Fair value | $3.49 | – |
| Margin of safety | −89.9% | – |
| Growth | ||
| Revenue growth (TTM) | −1.1% (better) | −25.7% |
| Revenue growth, 5Y average | 3.5% | – |
| Profitability | ||
| Operating margin | −30.8% (better) | −184% |
| Net margin | −34.9% (better) | −189% |
| FCF margin | 2.2% | – |
| Return on equity | −48.1% | – |
| Return on invested capital | −59.7% | – |
| Financial health | ||
| Interest coverage | −31.1× | −21.9× (better) |
| Current ratio | 0.96 | 1.66 (better) |
| Altman Z-score | 0.50 (better) | −14.29 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 22.6% | – |
| Buyback yield | 0.07% | – |
| Shareholder yield | 22.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 16.5% | 27.1% |
| Held by insiders | 80.2% | – |
| Insider net buying, 12 months | – | $211K |
| Short interest, % of float | 10.1% | – |
Go deeper
- CPIX stock overview
- CPIX income statement
- CPIX valuation and score
- VRCA stock overview
- VRCA income statement
- VRCA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.